CJC-1295 no DAC + Ipamorelin is a research blend that combines two peptides acting on the growth hormone axis through different receptors. CJC-1295 no DAC is a modified analog of growth hormone-releasing hormone (GHRH), and ipamorelin is a selective agonist of the ghrelin receptor. Because the two act on complementary pathways, the pairing is one of the most studied combinations in growth hormone secretagogue research.
What is CJC-1295 no DAC + Ipamorelin?
The blend contains two separate peptides supplied together in one vial.
CJC-1295 no DAC, also known as modified GRF (1-29) or Mod GRF 1-29, is a 29-amino-acid peptide based on the first 29 residues of human GHRH, the shortest portion of the hormone that retains full activity. Four amino acid substitutions make it more resistant to breakdown by the enzyme DPP-4 than the native sequence. The no DAC label distinguishes it from CJC-1295 with DAC, which carries a drug affinity complex that binds albumin and greatly extends its presence in circulation. Without DAC, the peptide is short-acting, which is why it is often studied for its effects on natural, pulse-like release patterns.
Ipamorelin is a synthetic pentapeptide in the growth hormone-releasing peptide (GHRP) family. It acts on the growth hormone secretagogue receptor (GHS-R1a), the same receptor used by the hormone ghrelin. In animal research it has been described as notably selective, stimulating growth hormone release with little effect on cortisol or prolactin compared with earlier GHRPs.
Neither peptide is an FDA-approved medicine. For context, a different GHRH analog, tesamorelin, is FDA-approved as Egrifta. PRIME supplies CJC-1295 no DAC + Ipamorelin as a research blend for laboratory use only.
How CJC-1295 no DAC + Ipamorelin works: mechanism studied in research
Growth hormone release from the pituitary is controlled by a balance of signals. GHRH stimulates release, somatostatin suppresses it, and ghrelin acts through its own receptor to amplify release. The blend targets two of these inputs at once.
- GHRH receptor (CJC-1295 no DAC): activation on somatotroph cells raises intracellular cAMP and promotes growth hormone synthesis and release.
- Ghrelin receptor (ipamorelin): activation triggers a separate calcium-dependent signaling route and is thought to counter somatostatin tone.
Research on combining a GHRH analog with a ghrelin receptor agonist has explored whether acting on both pathways produces a larger or more pronounced growth hormone pulse than either alone. This complementary action is the main scientific reason the two are studied together. Downstream, growth hormone drives production of IGF-1, mainly in the liver, so IGF-1 is a common readout in this line of research.
The pairing also reflects a practical research consideration. A short-acting GHRH analog preserves the normal on and off rhythm of pituitary release, while a selective ghrelin receptor agonist adds a second stimulus without the broader hormonal activity seen with older secretagogues. Studying the two together lets researchers look at pulse amplitude, timing and downstream IGF-1 signaling within a single experimental design.
Areas of research
Studies involving GHRH analogs, ghrelin receptor agonists and their combination cover several areas:
- Growth hormone pulsatility and pituitary physiology
- The GH and IGF-1 axis in animal models
- Synergy between GHRH and ghrelin receptor signaling
- Body composition, muscle and bone in preclinical models
- Receptor selectivity and effects on cortisol and prolactin
- Ghrelin receptor biology in gut motility research
These are research questions, not established uses. Neither peptide is approved to treat any condition, and results from animal and early studies should not be read as evidence of benefit in people.
Key facts table
| Property | CJC-1295 no DAC | Ipamorelin |
|---|---|---|
| Class | GHRH analog | Ghrelin receptor agonist (GHRP family) |
| Structure | 29-amino-acid modified GRF (1-29) | Synthetic pentapeptide |
| Target | GHRH receptor | GHS-R1a (ghrelin receptor) |
| Other names | Mod GRF 1-29, modified GRF (1-29) | NNC 26-0161 |
| Form supplied | Both peptides together as a lyophilized powder in one sealed vial | Both peptides together as a lyophilized powder in one sealed vial |
| Research status | Research compounds; not FDA-approved medicines | Research compounds; not FDA-approved medicines |
| Storage | Lyophilized: cold, dry and dark. Reconstituted: refrigerated and protected from light | Lyophilized: cold, dry and dark. Reconstituted: refrigerated and protected from light |
Handling and storage of the blend in the lab
The blend is supplied as a lyophilized powder, the most stable form for transport and storage. Unopened vials are best kept cold, dry and away from light.
When a solution is needed, researchers commonly reconstitute with bacteriostatic water using sterile technique: let the vial reach room temperature, swab the stopper, add diluent slowly down the vial wall, and swirl gently rather than shaking. Label the vial with the date and concentration used, then keep it refrigerated and protected from light, using it within the period set by your lab's procedures.
One point is specific to blends. Because both peptides are pre-combined, their ratio is fixed by the vial and cannot be adjusted afterward. Experiments that need to vary each compound independently are better served by the single peptides, such as Ipamorelin and CJC-1295 NO DAC, supplied separately.
Quality and lab results
With a blend, the certificate of analysis should confirm that both peptides are present and correctly identified. Every PRIME batch has a published COA, and you can see the report for each batch on our lab results page. A COA typically confirms identity by mass spectrometry and reports purity by HPLC. Match the lot number on your vial to the report and keep a copy with your lab records.
Related research
For a closer look at how the two components differ, read CJC-1295 vs Ipamorelin. Each component also has its own guide: the CJC-1295 no DAC research guide and the Ipamorelin research guide.
CJC-1295 no DAC + Ipamorelin FAQ
Why are CJC-1295 and Ipamorelin combined?
They act on different receptors that both regulate growth hormone release: the GHRH receptor and the ghrelin receptor. Research has explored whether acting on both pathways together produces a stronger release signal than either alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC carries a drug affinity complex that binds albumin and greatly extends its time in circulation. CJC-1295 no DAC, also called Mod GRF 1-29, lacks that group and is short-acting.
Is CJC-1295 the same as Mod GRF 1-29?
CJC-1295 no DAC and Mod GRF 1-29 are commonly used names for the same modified 29-amino-acid GHRH analog. The name CJC-1295 on its own often refers to the DAC version, so it is worth checking the label.
Is Ipamorelin FDA approved?
No. Ipamorelin and CJC-1295 no DAC are research compounds and are not FDA-approved medicines. PRIME sells this blend for laboratory research use only.
How should the blend be stored?
Keep the lyophilized blend cold, dry and away from light. Once reconstituted for lab use, store it refrigerated, protected from light, and use it within your lab's defined period.
For laboratory research use only. Not for human consumption. Not a drug, food or cosmetic.